Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 395 Shares

Posted by George Bondi on Jun 15th, 2026

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) SVP Arjun Agarwal sold 395 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55. Following the completion of the transaction, the senior vice president owned 16,899 shares of the company’s stock, valued at approximately $1,177,691.31. The trade was a 2.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total value of $659,481.48.
On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Performance

Shares of NASDAQ:ORKA traded down $1.03 during midday trading on Monday, reaching $68.86. 1,002,319 shares of the company’s stock traded hands, compared to its average volume of 1,071,721. Oruka Therapeutics, Inc. has a one year low of $10.77 and a one year high of $91.00. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -35.49 and a beta of -0.25. The stock has a 50 day moving average of $63.71 and a 200 day moving average of $44.31.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. Sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Analysts Set New Price Targets

ORKA has been the topic of several research reports. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 14th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. UBS Group increased their target price on Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Barclays raised their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Finally, Stifel Nicolaus increased their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $131.30.

Get Our Latest Stock Report on ORKA

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its position in shares of Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares during the period. Royal Bank of Canada increased its stake in shares of Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $39,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.